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BACKGROUND
The combination of bortezomib, melphalan, and prednisone is a standard treatment 
for patients with newly diagnosed multiple myeloma who are ineligible for autologous 
stem-cell transplantation. Daratumumab has shown efficacy in combination with 
standard-of-care regimens in patients with relapsed or refractory multiple myeloma.
METHODS
In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed mul-
tiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles 
of bortezomib, melphalan, and prednisone either alone (control group) or with dara-
tumumab (daratumumab group) until disease progression. The primary end point was 
progression-free survival.
RESULTS
At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month 
progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in 
the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard 
ratio for disease progression or death, 0.50; 95% CI, 0.38 to 0.65; P<0.001). The overall 
response rate was 90.9% in the daratumumab group, as compared with 73.9% in the 
control group (P<0.001), and the rate of complete response or better (including strin-
gent complete response) was 42.6%, versus 24.4% (P<0.001). In the daratumumab 
group, 22.3% of the patients were negative for minimal residual disease (at a threshold 
of 1 tumor cell per 105 white cells), as compared with 6.2% of those in the control 
group (P<0.001). The most common adverse events of grade 3 or 4 were hematologic: 
neutropenia (in 39.9% of the patients in the daratumumab group and in 38.7% of those 
in the control group), thrombocytopenia (in 34.4% and 37.6%, respectively), and ane-
mia (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 infections was 23.1% 
in the daratumumab group and 14.7% in the control group; the rate of treatment 
discontinuation due to infections was 0.9% and 1.4%, respectively. Daratumumab- 
associated infusion-related reactions occurred in 27.7% of the patients.
CONCLUSIONS
Among patients with newly diagnosed multiple myeloma who were ineligible for stem-
cell transplantation, daratumumab combined with bortezomib, melphalan, and pred-
nisone resulted in a lower risk of disease progression or death than the same regimen 
without daratumumab. The daratumumab-containing regimen was associated with 
more grade 3 or 4 infections. (Funded by Janssen Research and Development; ALCYONE 
ClinicalTrials.gov number, NCT02195479.)
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The risk of multiple myeloma in-creases with age,1-3 and despite progress in the development of effective treatment, 
the disease remains incurable.4-7 The most widely 
approved regimens for elderly patients are lena-
lidomide plus dexamethasone8 and — outside 
the United States — melphalan, prednisone, and 
thalidomide9 and melphalan, prednisone, and 
bortezomib.10 These regimens are associated 
with a progression-free survival of 18 months to 
2 years and an overall survival of 4 to 5 years.10-12
Daratumumab is a human IgGκ monoclonal 
antibody that targets CD38. Its multifaceted mech-
anisms of action include direct antitumor ef-
fects13-15 and an immunomodulatory component 
that results in depletion of immunosuppressive 
cells and clonal expansion of cytotoxic T cells.16
In patients with at least one previous line of 
therapy, daratumumab plus standard-of-care reg-
imens (bortezomib–dexamethasone [CASTOR 
trial]17 and lenalidomide–dexamethasone [POLLUX 
trial]18) significantly prolonged progression-free 
survival and induced higher response rates. These 
daratumumab-based combinations reduced the 
risk of disease progression or death by more 
than 60%.17,18
The VISTA (Velcade as Initial Standard Ther-
apy in Multiple Myeloma: Assessment with Mel-
phalan and Prednisone) trial established fixed-
duration treatment with bortezomib, melphalan, 
and prednisone as an effective therapy for pa-
tients with newly diagnosed multiple myeloma 
who are ineligible for stem-cell transplantation.10 
The GIMEMA (Gruppo Italiano Malattie Emato-
logiche dell’Adulto)9 and PETHEMA (Programa 
Español de Tratamientos en Hematología)19 trials 
improved dosing by reducing toxicity without 
sacrificing efficacy. Treatment with daratumu-
mab plus bortezomib, melphalan, and prednisone 
was evaluated in a phase 1 safety trial.20 In this 
article, we report a prespecified interim analysis 
of this randomized, phase 3 trial (ALCYONE) of 
bortezomib, melphalan, and prednisone with or 
without daratumumab in patients with newly 
diagnosed multiple myeloma who were ineligible 
for autologous stem-cell transplantation.
Me thods
Trial Design and Oversight
This multicenter, randomized, open-label, active-
controlled phase 3 trial enrolled patients between 
February 9, 2015, and July 14, 2016, at 162 sites 
in 25 countries across North and South America, 
Europe, and the Asia–Pacific region. Independent 
ethics committees or institutional review boards 
at each site approved the protocol (available with 
the full text of this article at NEJM.org). The 
trial was conducted in accordance with the prin-
ciples of the Declaration of Helsinki and the 
International Conference on Harmonisation–
Good Clinical Practice guidelines. All the pa-
tients provided written informed consent. Jans-
sen Research and Development sponsored this 
trial and designed it in collaboration with the 
academic authors. Data were compiled and main-
tained by the sponsor. Authors were given access 
to the data and were not restricted by confiden-
tiality agreements. Professional medical writers 
who were funded by the sponsor prepared the 
manuscript. All the authors reviewed and revised 
the manuscript and approved it for submission. 
The sponsor and authors vouch for the accuracy 
and completeness of the data from the prespeci-
fied interim analysis and for the adherence of 
the trial to the protocol.
Patients
We recruited patients with newly diagnosed, doc-
umented multiple myeloma21 who were not eli-
gible for high-dose chemotherapy with stem-cell 
transplantation owing to coexisting conditions 
or an age of 65 years or older. These patients had 
a hemoglobin level of 7.5 g or more per deciliter, 
an absolute neutrophil count of 1.0×109 or more 
per liter, aspartate aminotransferase and alanine 
aminotransferase levels of 2.5 or fewer times the 
upper limit of the normal range, a total bilirubin 
level of 1.5 or fewer times the upper limit of the 
normal range, a creatinine clearance of 40 ml or 
more per minute, a corrected serum calcium 
level of 14 mg or less per deciliter (≤3.5 mmol 
per liter), a platelet count of 70×109 or more per 
liter (if <50% of bone marrow nucleated cells 
were plasma cells; otherwise, platelet count of 
>50×109 per liter), and an Eastern Cooperative 
Oncology Group performance status of 0 to 2 
(on a 5-point scale, with higher numbers indi-
cating greater disability).
We excluded patients with primary amyloido-
sis, monoclonal gammopathy of undetermined 
significance, smoldering multiple myeloma, 
Waldenström’s macroglobulinemia (or other con-
ditions in which IgM paraprotein is present in 
the absence of a clonal plasma cell infiltration 
with lytic bone lesions), previous systemic therapy 
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or stem-cell transplantation, cancer within 3 years 
before randomization (exceptions were squamous-
cell and basal-cell carcinomas of the skin, carci-
noma in situ of the cervix, and any cancer that 
was considered to be cured with minimal risk of 
recurrence within 3 years), peripheral neuropathy, 
or grade 2 or higher neuropathic pain (as defined 
by the National Cancer Institute Common Termi-
nology Criteria for Adverse Events [NCI CTCAE], 
version 4).
Trial Treatments
Patients were randomly assigned by means of an 
interactive Web-response system in a 1:1 ratio to 
daratumumab in combination with bortezomib, 
melphalan, and prednisone (daratumumab group) 
or bortezomib, melphalan, and prednisone alone 
(control group) (Fig. S1 in the Supplementary 
Appendix, available at NEJM.org). Randomiza-
tion was stratified according to International 
Staging System (ISS) disease stage (I, II, or III, 
with higher stages indicating a poorer progno-
sis; stages are determined on the basis of albu-
min and β2-microglobulin levels), geographic re-
gion (Europe vs. other), and age (<75 years vs. ≥75 
years). Treatment assignments were not blinded.
All the patients received up to nine (42-day) 
cycles of subcutaneous bortezomib (1.3 mg per 
square meter of body-surface area, twice weekly 
on weeks 1, 2, 4, and 5 of cycle 1 and once 
weekly on weeks 1, 2, 4, and 5 of cycles 2 
through 9), oral melphalan (9 mg per square 
meter, once daily on days 1 through 4 of each 
cycle), and oral prednisone (60 mg per square 
meter, once daily on days 1 through 4 of each 
cycle). In the experimental group, intravenous 
daratumumab at a dose of 16 mg per kilogram 
of body weight was administered with oral or 
intravenous dexamethasone (to manage infusion 
reactions; see the Supplementary Appendix) at 
a dose of 20 mg once weekly in cycle 1, every 
3 weeks in cycles 2 through 9, and every 4 weeks 
thereafter until disease progression or unaccept-
able toxic effects. Dexamethasone at a dose of 
20 mg was substituted for prednisone on day 1 
of each cycle.
End Points and Assessments
The primary end point was progression-free sur-
vival, defined as the time from randomization to 
either disease progression or death. Key efficacy 
secondary end points were the overall response 
rate and the rates of very good partial response 
or better (comprising very good partial, com-
plete, and stringent complete responses) (Table 
S1 in the Supplementary Appendix), complete re-
sponse or better (comprising complete and strin-
gent complete responses), negative status for 
minimal residual disease (at a threshold of 1 tu-
mor cell per 105 white cells),22 and overall sur-
vival. Other end points were safety, side-effect 
profile, time to response, and duration of re-
sponse. Progressive disease was defined accord-
ing to International Myeloma Working Group 
criteria.23,24 Definitions of these end points are 
provided in the Supplementary Appendix.
Efficacy assessments, based on biochemical 
variables that included serum and urine mono-
clonal proteins and serum free light chains, were 
performed at a central laboratory. Samples were 
collected every 3 weeks during the first year af-
ter randomization, every 4 weeks during the 
second year, and every 8 weeks thereafter until 
disease progression. If daratumumab interference 
with serum paraprotein assessment was suspect-
ed (i.e., IgGκ-positive samples), immunofixation 
reflex assays were performed to confirm com-
plete responses.25 Minimal residual disease was 
assessed by means of an Adaptive Biotechnolo-
gies clonoSEQ next-generation sequencing assay 
(version 2.0) with the use of bone marrow aspi-
rate collected at screening, at the time of confir-
mation of complete response or stringent com-
plete response, and at 12, 18, 24, and 30 months 
after the first dose in patients having a complete 
response or stringent complete response (see the 
Supplementary Appendix). Safety assessments in-
cluded evaluation of adverse events graded in 
accordance with the NCI CTCAE (version 4), 
clinical laboratory testing, electrocardiograms, 
measurement of vital signs, and physical exami-
nations.26
Statistical Analysis
The primary analysis population was the inten-
tion-to-treat population of all the patients who 
underwent randomization. The safety population 
comprised patients who received any dose of 
trial treatment. Continuous variables were sum-
marized with descriptive statistics, and categori-
cal variables were summarized in frequency tables. 
Time-to-event variables were evaluated with the 
Kaplan–Meier method. Response to trial treat-
ment was determined with the use of a validated 
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computer algorithm, as described previously.17,18 
Binary end points, such as response rate, were 
assessed with a stratified Cochran–Mantel–
Haenszel test, and an odds ratio and two-sided 
95% confidence interval were calculated. If the 
between-group difference in the primary end 
point was significant at the time of the second 
interim analysis, the efficacy secondary end 
points of overall response rate and rates of very 
good partial response or better, complete re-
sponse or better, and negative status for mini-
mal residual disease, as ordered here, were se-
quentially tested, each with an overall two-sided 
alpha level of 0.05.
Of two planned interim analyses, the first 
evaluated only safety after 100 patients had re-
ceived at least two treatment cycles or had dis-
continued treatment. The second, reported here, 
assessed safety and efficacy when 231 events of 
disease progression or death had occurred (i.e., 
64% of the planned 360 events for the final 
analysis; an alpha of 0.0103 was spent). The final 
overall survival analysis will occur after 330 deaths.
A sample size of 350 patients per group (under 
the assumption of an annual dropout rate of 5%) 
was estimated to provide 85% power to detect a 
27.6% lower risk of disease progression or death 
in the daratumumab group than in the control 
group, with the use of a log-rank test with a 
two-sided alpha level of 0.05. The primary effi-
cacy end point was estimated with the Kaplan–
Meier method, and the treatment effect (hazard 
ratio) and its two-sided 95% confidence interval 
were estimated with a stratified Cox regression 
model. Statistical significance was evaluated with 
a stratified log-rank test based on the predeter-
mined alpha level at the clinical cutoff date. 
Additional statistical methods are described in 
the Supplementary Appendix.
R esult s
Patients and Treatment
Of 706 patients, 350 were assigned to the dara-
tumumab group and 356 to the control group. 
Demographic and clinical characteristics were 
generally well balanced between the two groups 
(Table 1, and Table S2 in the Supplementary 
Appendix). The median age at baseline was 
71.0 years (range, 40 to 93), and the median 
time since diagnosis was 0.8 months (range, 0.1 
to 25.3).
A total of 700 patients (346 in the dara-
tumumab group and 354 in the control group) 
received the assigned intervention. At the clini-
cal cutoff date (June 12, 2017), a total of 276 
patients (79.8%) in the daratumumab group and 
220 patients (62.1%) in the control group had 
completed all nine cycles of bortezomib, mel-
phalan, and prednisone; 17 patients in each 
group were still receiving treatment with bor-
tezomib, melphalan, and prednisone. Per proto-
col, all the patients in the control group discon-
tinued treatment after nine cycles and all the 
patients in the daratumumab group continued 
daratumumab as monotherapy. During the first 
nine cycles, 19.4% of the patients in the dara-
tumumab group and 33.1% of the patients in the 
control group discontinued treatment; a lower 
percentage of patients in the daratumumab group 
than in the control group discontinued treatment 
owing to disease progression (6.6% vs. 13.3%) 
and adverse events (4.9% vs. 9.3%), and a similar 
percentage discontinued treatment owing to death 
(3.2% and 2.3%, respectively). Beyond cycle 9, 
the most common reasons for discontinuation 
during daratumumab treatment were progressive 
disease (8.7%) and death (0.6%) (Fig. S2 in the 
Supplementary Appendix).
The median duration of treatment was 14.7 
months (63.9 weeks) in the daratumumab group 
and 12.0 months (52.1 weeks) in the control 
group. The median relative dose intensity (the 
sum of all doses received in all cycles divided by 
the number of treatment cycles) of bortezomib 
and melphalan was the same in both treatment 
groups (bortezomib, 5.5 mg per square meter per 
cycle [of a maximum potential dose of 10.4 mg 
per square meter in cycle 1 and 5.2 mg per 
square meter per cycle in cycles 2 through 9]; 
melphalan, 35.0 mg per square meter per cycle 
[of a maximum potential dose of 36 mg per 
square meter per cycle]). In the daratumumab 
group, prednisone equivalents were calculated 
because other glucocorticoids were also used. 
The median equivalent dose intensity of predni-
sone in the daratumumab group was 251.8 mg 
per square meter per cycle, and the actual dose 
intensity in the control group was 237.3 mg per 
square meter per cycle (of a maximum potential 
prednisone dose of 240 mg per square meter per 
cycle). The median relative dose intensity of dara-
tumumab was 30.9 mg per kilogram per cycle 
(95.7 mg per kilogram in cycle 1, 32.0 mg per 
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kilogram per cycle in cycles 2 through 9, and 
16.0 mg per kilogram per cycle in cycles 10 or 
more). The median cumulative dose of bortezo-
mib was 46.9 mg per square meter in the dara-
tumumab group and 42.2 mg per square meter 
in the control group.
Efficacy
The primary efficacy end point was progression-
free survival. At the clinical cutoff date, an event 
of disease progression or death had occurred in 
88 patients (25.1%) in the daratumumab group 
versus 143 patients (40.2%) in the control group. 
The hazard ratio for disease progression or death 
in the daratumumab group versus the control 
group was 0.50 (95% confidence interval [CI], 
0.38 to 0.65; P<0.001) (Fig. 1). The Kaplan–Meier 
estimate of the 12-month rate of progression-
free survival was 86.7% (95% CI, 82.6 to 89.9) in 
the daratumumab group and 76.0% (95% CI, 
71.0 to 80.2) in the control group; the 18-month 
rate of progression-free survival was 71.6% (95% 
CI, 65.5 to 76.8) in the daratumumab group and 
50.2% (95% CI, 43.2 to 56.7) in the control group. 
Characteristic
Daratumumab Group 
(N = 350)
Control Group 
(N = 356)
Age
Median (range) — yr 71.0 (40–93) 71.0 (50–91)
Distribution — no. (%)
<65 yr 36 (10.3) 24 (6.7)
65–74 yr 210 (60.0) 225 (63.2)
≥75 yr 104 (29.7) 107 (30.1)
ECOG performance status — no. (%)†
0 78 (22.3) 99 (27.8)
1 182 (52.0) 173 (48.6)
2 90 (25.7) 84 (23.6)
ISS disease stage — no. (%)‡
I 69 (19.7) 67 (18.8)
II 139 (39.7) 160 (44.9)
III 142 (40.6) 129 (36.2)
Cytogenetic profile — no./total no. (%)§
Standard risk 261/314 (83.1) 257/302 (85.1)
High risk¶ 53/314 (16.9) 45/302 (14.9)
Median time since initial diagnosis of multiple  
myeloma (range) — mo
0.8 (0.1–11.4) 0.8 (0.1–25.3)‖
*  The intention-to-treat population was defined as all the patients who had undergone randomization. Post hoc analyses 
showed no significant differences between the two groups in the characteristics evaluated at baseline. Percentages may 
not sum to 100 because of rounding.
†  Eastern Cooperative Oncology Group (ECOG) performance status is scored on a scale from 0 to 5, with 0 indicating no 
symptoms and higher scores indicating increasing disability.
‡  The International Staging System (ISS) disease stage is derived on the basis of the combination of serum β2-micro-
globulin and albumin levels. Higher stages indicate more severe disease.
§  Cytogenetic risk was based on fluorescence in situ hybridization or karyotype testing. Cytogenetic data assessed by 
means of next-generation sequencing for the total intention-to-treat population were not available at the data cutoff 
date, and analysis is ongoing.
¶  These patients had at least one high-risk abnormality: del17p, t(4;14), or t(14;16).
‖  At the time of initial diagnosis, the patient with a time since initial diagnosis of multiple myeloma of 25.3 months did 
meet International Myeloma Working Group diagnostic criteria for multiple myeloma with a hemoglobin level of less 
than 10 g per deciliter and at least 10% plasma cells on examination of the bone marrow. A decision was made by the 
physician not to initiate treatment at the time of diagnosis. The patient’s disease was stable and actively monitored 
 until treatment was begun at a later date.
Table 1. Demographic and Clinical Characteristics in the Intention-to-Treat Population at Baseline.*
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The median progression-free survival was not 
reached (95% CI, could not be estimated) in the 
daratumumab group versus 18.1 months (95% 
CI, 16.5 to 19.9) in the control group (P<0.001).
Prespecified subgroup analyses of progression-
free survival showed that the superiority of 
daratumumab in combination with bortezomib, 
melphalan, and prednisone over bortezomib, 
melphalan, and prednisone alone was consistent 
across all subgroups, including patients 75 years 
of age or older and those with a poor prognosis 
(ISS disease stage III, renal impairment, or high-
risk cytogenetic profile) (Fig. 2). Although the 
hazard ratio for disease progression or death in 
the daratumumab group was higher among pa-
tients with a high-risk cytogenetic profile (0.78) 
than among those with a standard-risk cytoge-
netic profile (0.39), the results still favored the 
daratumumab group over the control group; inter-
pretation of the results in patients with a high-
risk cytogenetic profile is limited because of the 
small number of patients.
Post hoc analyses of progression-free survival 
according to disease stage as defined by revised 
ISS criteria27 showed results in patients with dis-
ease stage III (hazard ratio for disease progres-
sion or death, 0.75) (Table S3 in the Supple-
mentary Appendix) that were similar to those 
in patients with a high-risk cytogenetic profile.
Prespecified key efficacy secondary end points 
were sequentially tested with the use of a hierar-
chical approach. The overall response rate was 
90.9% in the daratumumab group and 73.9% in 
the control group (P<0.001) (Table 2). The rate of 
very good partial response or better was signifi-
cantly higher in the daratumumab group than in 
the control group (71.1% vs. 49.7%, P<0.001), as 
was the rate of complete response or better 
(42.6% vs. 24.4%, P<0.001). Consistent with the 
higher rates of complete or stringent complete 
response, the rate of negative status for minimal 
residual disease (at a threshold of 1 tumor cell 
per 105 white cells) was more than 3 times as 
high in the daratumumab group as in the con-
trol group (22.3% vs. 6.2%, P<0.001). Negative 
status for minimal residual disease was associ-
ated with longer progression-free survival than 
positive status, irrespective of trial treatment. In 
patients with persistent minimal residual dis-
ease, progression-free survival was longer in the 
daratumumab group than in the control group 
(Fig. S3 in the Supplementary Appendix).
The median time to response was 0.79 months 
in the daratumumab group and 0.82 months in 
the control group, and the median time to best 
response was 4.9 months and 4.1 months, re-
spectively. The median duration of response was 
not reached (95% CI, could not be estimated) in 
the daratumumab group and 21.3 months (95% 
CI, 18.4 to could not be estimated) in the control 
group. The estimated percentage of patients who 
continued to have a response after 18 months was 
77.2% in the daratumumab group and 60.4% in 
the control group.
At a median follow-up of 16.5 months, death 
had occurred in 45 patients in the daratumumab 
group and 48 patients in the control group (Fig. 
S4 in the Supplementary Appendix). The median 
overall survival was not reached in either group. 
Follow-up for long-term survival is ongoing.
Figure 1. Progression-free Survival.
Shown are the results of the Kaplan–Meier estimates of progression-free 
survival among patients in the intention-to-treat population, which includ-
ed all the patients who underwent randomization. The daratumumab group 
received treatment with daratumumab, bortezomib, melphalan, and pred-
nisone; the control group received treatment with bortezomib, melphalan, 
and prednisone alone. The interim analysis of median progression-free sur-
vival was performed after 231 events of disease progression or death had 
occurred (64% of the planned 360 events for the final analysis); the results 
of the analysis crossed the prespecified stopping boundary. NE denotes 
could not be estimated.
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Safety
The secondary objective of safety was evaluated 
with the use of adverse-event reporting. The 
most common adverse events of any grade (in 
≥20% of the patients in either group) were neu-
tropenia (in 49.7% of the patients in the daratum-
umab group and 52.5% of those in the control 
group), thrombocytopenia (in 48.8% and 53.7%, 
respectively), peripheral sensory neuropathy (in 
28.3% and 34.2%, respectively), anemia (in 28.0% 
and 37.6%, respectively), upper respiratory tract 
infection (in 26.3% and 13.8%, respectively), 
Figure 2. Prespecified Subgroup Analysis of Progression-free Survival.
Shown are the results of an analysis of progression-free survival in prespecified subgroups of the intention-to-treat population that were 
defined according to baseline characteristics. The daratumumab group received treatment with daratumumab, bortezomib, melphalan, 
and prednisone; the control group received treatment with bortezomib, melphalan, and prednisone alone. Race was determined by the 
investigator. Impaired baseline hepatic function includes mild impairment (total bilirubin level ≤ the upper limit of the normal range 
[ULN] and aspartate aminotransferase level > the ULN, or total bilirubin level > the ULN and ≤1.5 times the ULN), moderate impairment 
(total bilirubin level >1.5 times and ≤3 times the ULN), and severe impairment (total bilirubin level >3 times the ULN). The International 
Staging System (ISS) consists of three stages, with higher stages indicating more severe disease: stage I, serum β2-microglobulin level 
less than 3.5 mg per liter (300 nmol per liter) and albumin level 3.5 g or more per deciliter; stage II, neither stage I nor III; and stage III, 
serum β2-microglobulin level 5.5 mg or more per liter (≥470 nmol per liter). The subgroup analysis for the type of multiple myeloma was 
performed on data from patients who had measurable disease in serum. A high-risk cytogenetic profile was defined by a finding of t(4;14), 
t(14;16), or del17p on fluorescence in situ hybridization testing or a finding of t(4;14) or del17p on karyotype testing. Eastern Cooperative 
Oncology Group (ECOG) performance status is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher scores indicat-
ing increasing disability. NE denotes could not be estimated.
1.0 10.0
Control BetterDaratumumab Better
Sex
Male
Female
Age
<75 yr
≥75 yr
Race
White
Other
Geographic region
Europe
Other
Baseline creatinine clearance
≤60 ml/min
>60 ml/min
Baseline hepatic function
Normal
Impaired
ISS disease stage
I
II
III
Type of multiple myeloma
IgG
Non-IgG
Cytogenetic profile at trial entry
High risk
Standard risk
ECOG performance status
0
1 or 2
Daratumumab
Group Hazard Ratio (95% CI)
Control
GroupSubgroup
0.60 (0.42–0.87)
0.41 (0.28–0.61)
0.49 (0.36–0.68)
0.53 (0.32–0.85)
0.56 (0.42–0.74)
0.26 (0.12–0.57)
0.57 (0.43–0.76)
0.22 (0.10–0.50)
0.36 (0.24–0.56)
0.63 (0.45–0.88)
0.53 (0.40–0.71)
0.42 (0.22–0.80)
0.50 (0.24–1.05)
0.49 (0.32–0.73)
0.53 (0.35–0.79)
0.45 (0.32–0.64)
0.81 (0.48–1.37)
0.78 (0.43–1.43)
0.39 (0.28–0.55)
0.40 (0.21–0.74)
0.52 (0.39–0.70)
0.1
50/160
38/190
60/246
28/104
79/297
9/53
80/289
8/61
32/150
56/200
73/301
15/46
12/69 
35/139
41/142
51/207
26/82  
24/53  
54/261
14/78  
74/272
68/167
75/189
101/249  
42/107
121/304
22/52  
121/295  
22/61  
63/145
80/211
115/303  
28/52  
18/67  
70/160
55/129
93/218
29/83  
19/45  
108/257  
35/99  
108/257  
no. of progression events
or deaths/total no.
Daratumumab
Group
Control
Group
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
NE
18.0
NE
NE
NE
18.1
17.9
17.9
20.4
18.1
16.8
18.1
17.5
16.9
18.3
19.1
13.5
19.4
17.5
16.8
17.4
NE
18.1
17.4
19.4
17.6
median progression-free
survival (mo)
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV STUDI LA SAPIENZA on January 15, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 378;6 nejm.org February 8, 2018 525
Dar atumumab for Untreated Myeloma
diarrhea (in 23.7% and 24.6%, respectively), py-
rexia (in 23.1% and 20.9%, respectively), and nau-
sea (in 20.8% and 21.5%, respectively) (Table 3, 
and Table S4 in the Supplementary Appendix). 
The most frequently reported adverse events of 
grade 3 or 4 (in ≥10% of patients in either 
group) were hematologic, including neutropenia 
(in 39.9% of the patients in the daratumumab 
group and 38.7% of those in the control group), 
thrombocytopenia (in 34.4% and 37.6%, respec-
tively), and anemia (in 15.9% and 19.8%, respec-
tively) (Table 3). The rate of grade 3 or 4 infections 
was higher in the daratumumab group than in 
the control group (23.1% vs. 14.7%); the most 
common grade 3 or 4 infection was pneumonia, 
with a higher rate in the daratumumab group 
than in the control group (11.3% vs. 4.0%) (Ta-
ble 3). Most infections, including pneumonia, 
resolved (in 87.9% of the patients in the daratum-
umab group and 86.5% of those in the control 
group), and rates of discontinuation of trial treat-
ment owing to infections did not differ substan-
tially between the two groups (0.9% and 1.4%, 
respectively). One patient in each group (0.3%) 
discontinued trial treatment owing to pneumo-
nia of any grade. Death due to infection occurred 
in five patients (1.4%) in the daratumumab 
group (two patients died from pneumonia, and 
one patient each died from peritonitis, septic 
shock, and upper respiratory tract infection) and 
in four patients (1.1%) in the control group (one 
patient each died from septic shock, candida-
related sepsis, bacterial pneumonia, and sepsis).
Serious adverse events occurred in 41.6% of 
the patients in the daratumumab group and 
32.5% of those in the control group. Pneumonia 
Variable
Daratumumab Group 
(N = 350)
Control Group 
(N = 356) P Value
Overall response
No. with response 318 263 —
Rate — % (95% CI) 90.9 (87.3–93.7) 73.9 (69.0–78.4) <0.001†
Best overall response — no. (%)
Complete response or better 149 (42.6) 87 (24.4) <0.001†
Stringent complete response‡ 63 (18.0) 25 (7.0) —
Complete response 86 (24.6) 62 (17.4) —
Very good partial response or better 249 (71.1) 177 (49.7) <0.001†
Very good partial response 100 (28.6) 90 (25.3) —
Partial response 69 (19.7) 86 (24.2) —
Stable disease 20 (5.7) 76 (21.3) —
Progressive disease 0 2 (0.6) —
Response could not be evaluated 12 (3.4) 15 (4.2) —
Negative status for minimal residual disease — no. (%)§ 78 (22.3) 22 (6.2) <0.001¶
*  Response was assessed on the basis of International Myeloma Working Group recommendations (details on the crite-
ria for disease responses are provided in the trial protocol). This analysis included patients who could be evaluated for 
response and had a confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening. In ad-
dition, patients must have received at least one dose of trial treatment and must have had at least one disease assess-
ment after the baseline visit. The following secondary end points were sequentially tested, each with an overall two-sided 
alpha level of 0.05, with the use of a hierarchical testing approach: overall response rate, rate of very good partial re-
sponse or better, rate of complete response or better, and rate of negative status for minimal residual disease.
†  The P value was calculated with the use of the Cochran–Mantel–Haenszel chi-square test.
‡  Criteria for a stringent complete response included the criteria for a complete response plus a normal free light-chain 
ratio and absence of clonal plasma cells, as assessed by immunohistochemical or immunofluorescence analysis or by 
two-color to four-color flow cytometry.
§  The threshold for minimal residual disease was defined as 1 tumor cell per 105 white cells. Status regarding minimal 
residual disease is based on postrandomization assessment conducted on bone marrow samples with the use of a vali-
dated next-generation sequencing assay (clonoSEQ Assay, version 2.0; Adaptive Biotechnologies) in accordance with 
International Myeloma Working Group guidelines on assessment of minimal residual disease.22
¶  The P value was calculated with the use of Fisher’s exact test.
Table 2. Summary of Responses and Status Regarding Minimal Residual Disease.*
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV STUDI LA SAPIENZA on January 15, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 378;6 nejm.org February 8, 2018526
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
(in 10.1% and 3.1%, respectively) was the most 
common. The rate of discontinuation of trial 
treatment due to adverse events was lower in the 
daratumumab group (4.9%) than in the control 
group (9.0%).
Adverse events within 30 days after the last 
trial treatment leading to death occurred in 14 
patients (4.0%) in the daratumumab group and 
16 patients (4.5%) in the control group. Daratum-
umab-related infusion reactions (mostly of 
grade 1 or 2) occurred in 27.7% of the patients, 
with the majority during the first infusion (Table 
S5 in the Supplementary Appendix). Grade 3 
infusion-related reactions occurred in 4.3% of 
the patients, and grade 4 reactions occurred in 
0.6%. The number of patients with a second 
primary cancer was similar in the two groups: 
8 patients (2.3%) in the daratumumab group and 
9 patients (2.5%) in the control group. Tumor 
lysis syndrome was reported in 2 patients (0.6%) 
in each group.
Discussion
In this phase 3 trial, daratumumab combined 
with bortezomib, melphalan, and prednisone re-
sulted in significantly longer progression-free 
survival than bortezomib, melphalan, and predni-
sone alone and was associated with a 50% lower 
risk of disease progression or death among pa-
tients with newly diagnosed multiple myeloma 
who were ineligible for stem-cell transplantation. 
Hierarchical testing of the key efficacy second-
ary end points supported the primary analysis, 
with significant differences in the depth of re-
sponse. For example, the sum of the rates of 
complete response and of stringent complete 
response was nearly twice as high in the dara-
tum umab group as in the control group, and 
the rate of negative status for minimal residual 
disease was more than three times as high.
Cross-trial comparisons have limitations, es-
pecially when inclusion criteria may vary on the 
Event
Daratumumab Group 
(N = 346)
Control Group 
(N = 354)
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Hematologic adverse events
Neutropenia 172 (49.7) 138 (39.9) 186 (52.5) 137 (38.7)
Thrombocytopenia 169 (48.8) 119 (34.4) 190 (53.7) 133 (37.6)
Anemia 97 (28.0) 55 (15.9) 133 (37.6) 70 (19.8)
Nonhematologic adverse events
Peripheral sensory neuropathy 98 (28.3) 5 (1.4) 121 (34.2) 14 (4.0)
Diarrhea 82 (23.7) 9 (2.6) 87 (24.6) 11 (3.1)
Pyrexia 80 (23.1) 2 (0.6) 74 (20.9) 2 (0.6)
Nausea 72 (20.8) 3 (0.9) 76 (21.5) 4 (1.1)
Infections 231 (66.8) 80 (23.1) 170 (48.0) 52 (14.7)
Upper respiratory tract infection 91 (26.3) 7 (2.0) 49 (13.8) 5 (1.4)
Pneumonia 53 (15.3) 39 (11.3) 17 (4.8) 14 (4.0)
Second primary cancer† 8 (2.3) NA 9 (2.5) NA
Any infusion-related reaction 96 (27.7) 17 (4.9) NA NA
*  The safety population included all the patients who received at least one dose of trial treatment. Adverse events of any 
grade that were reported in at least 20% of the patients in either treatment group and grade 3 or 4 adverse events that 
were reported in at least 10% of the patients in either treatment group are listed. NA denotes not applicable.
†  The presence of a second primary cancer was prespecified in the statistical analysis plan as an adverse event of clinical 
interest.
Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
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basis of the toxicity of the treatments given. How-
ever, the magnitude of benefit in the daratum-
umab group, as measured by the hazard ratio for 
disease progression or death (0.50), compares 
favorably with that in other randomized trials 
involving patients with newly diagnosed multi-
ple myeloma who were ineligible for stem-cell 
transplantation — specifically, the VISTA trial 
(hazard ratio, 0.61)28 and the FIRST (Frontline 
Investigation of Revlimid and Dexamethasone 
versus Standard Thalidomide) trial of lena-
lidomide and dexamethasone (hazard ratio, 0.72).8 
In addition, median progression-free survival in 
the control group (18.1 months) was consistent 
with that in the group receiving bortezomib, 
melphalan, and prednisone in the VISTA trial 
(18.3 months).10,28
Of the patients receiving daratumumab, 42.6% 
had a complete response or better and 18.0% 
had a stringent complete response. Furthermore, 
22.3% of the patients were negative for minimal 
residual disease. In this trial, negative status for 
minimal residual disease was associated with 
longer progression-free survival than positive 
status, irrespective of trial treatment. These re-
sults are consistent with those of the CASTOR29 
and POLLUX trials18 and of the IFM (Intergroupe 
Francophone du Myélome) 2009 Study30 of lena-
lidomide, bortezomib, and dexamethasone in pa-
tients with newly diagnosed multiple myeloma 
who were ineligible for stem-cell transplantation.
Although patients with a high-risk cytoge-
netic profile benefited from daratumumab treat-
ment, those with a standard-risk cytogenetic 
profile had a lower hazard ratio for disease pro-
gression or death. It should be noted that cyto-
genetic data were assessed at each site per local 
practice.
Combining daratumumab with bortezomib, 
melphalan, and prednisone did not increase over-
all toxicity. Except for infection, adverse events 
were balanced between the daratumumab and 
control groups, with a lower rate of peripheral 
sensory neuropathy in the daratumumab group.
Our trial shows that the combination of 
 daratumumab with bortezomib, melphalan, and 
prednisone resulted in significant clinical bene-
fits as compared with bortezomib, melphalan, 
and prednisone alone in patients with newly diag-
nosed multiple myeloma who were ineligible for 
stem-cell transplantation. Overall, daratumumab 
in combination with this standard-of-care regi-
men was associated with infusion-related reac-
tions and more infections, including a higher 
rate of pneumonia (which did not result in 
higher rates of discontinuation or death); the 
usual chemotherapy-related toxic effects were 
not increased by the addition of daratumumab.
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